{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:09:42Z","timestamp":1787220582982,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001414"],"award-info":[{"award-number":["UL1 TR001414"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS\/IRG \\u2013 98-279- 07"],"award-info":[{"award-number":["ACS\/IRG \\u2013 98-279- 07"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS111303"],"award-info":[{"award-number":["NS111303"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center","doi-asserted-by":"publisher","award":["P30CA062203"],"award-info":[{"award-number":["P30CA062203"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["NS109423"],"award-info":[{"award-number":["NS109423"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.phrs.2025.107697","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:08:34Z","timestamp":1741900114000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models"],"prefix":"10.1016","volume":"215","author":[{"given":"Christopher","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Lomeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Lepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh Kumar","family":"Nandwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil Shareef","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Bota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107697_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107697_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030324","article-title":"Current FDA-approved therapies for high-grade malignant gliomas","volume":"9","author":"Fisher","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2025.107697_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2025.107697_bib5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107697_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.107697_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","article-title":"Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells","volume":"15","author":"Li","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.107697_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.107697_bib10","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2025.107697_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib12","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.yexcr.2012.07.017","article-title":"Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications","volume":"318","author":"Yang","year":"2012","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2025.107697_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2007.01.047","article-title":"HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells","volume":"129","author":"Fukuda","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107697_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.274.5284.103","article-title":"Promotion of mitochondrial membrane complex assembly by a proteolytically inactive yeast Lon","volume":"274","author":"Rep","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107697_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41467-020-20597-z","article-title":"LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding","volume":"12","author":"Shin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107697_bib16","doi-asserted-by":"crossref","first-page":"13902","DOI":"10.1074\/jbc.M309642200","article-title":"DNA and RNA binding by the mitochondrial lon protease is regulated by nucleotide and protein substrate","volume":"279","author":"Liu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.celrep.2014.06.018","article-title":"ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity","volume":"8","author":"Quiros","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2025.107697_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.204","article-title":"Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species","volume":"4","author":"Cheng","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.107697_bib19","doi-asserted-by":"crossref","first-page":"77457","DOI":"10.18632\/oncotarget.12681","article-title":"Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma","volume":"7","author":"Di","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2025.107697_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biochi.2007.10.010","article-title":"Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors","volume":"90","author":"Bayot","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2025.107697_bib21","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1038\/s41467-021-23495-0","article-title":"Structures of the human LONP1 protease reveal regulatory steps involved in protease activation","volume":"12","author":"Shin","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2025.107697_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2025.107697_bib23","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/sj.onc.1203768","article-title":"Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide","volume":"19","author":"Patel","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107697_bib24","doi-asserted-by":"crossref","first-page":"7829438","DOI":"10.1155\/2017\/7829438","article-title":"Ratiometric sensing of hydrogen peroxide utilizing conformational change in fluorescent boronic acid polymers","volume":"2017","author":"Takeshima","year":"2017","journal-title":"J. Anal. Methods Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa021","article-title":"Bortezomib at therapeutic doses poorly passes the blood\u2013brain barrier and does not impair cognition","volume":"2","author":"Huehnchen","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.phrs.2025.107697_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40880-019-0424-2","article-title":"Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis","volume":"39","author":"Tang","year":"2019","journal-title":"Cancer Commun. (Lond. )"},{"key":"10.1016\/j.phrs.2025.107697_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040843","article-title":"The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma","volume":"13","author":"Maneix","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2025.107697_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101719","article-title":"Inhibition of mitochondrial LonP1 protease by allosteric blockade of ATP binding and hydrolysis via CDDO and its derivatives","volume":"298","author":"Lee","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib29","doi-asserted-by":"crossref","first-page":"25466","DOI":"10.18632\/oncotarget.4510","article-title":"Inhibition of Lon protease by triterpenoids alters mitochondria and is associated to cell death in human cancer cells","volume":"6","author":"Gibellini","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2025.107697_bib30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1039\/C6TX00220J","article-title":"Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2\/Omi","volume":"5","author":"Csizmadia","year":"2016","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.phrs.2025.107697_bib31","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/0008-5472.CAN-07-3036","article-title":"Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3","volume":"68","author":"Ahmad","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107697_bib32","doi-asserted-by":"crossref","first-page":"35764","DOI":"10.1074\/jbc.M607160200","article-title":"Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179","volume":"281","author":"Ahmad","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098896","article-title":"Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO","volume":"9","author":"Cleasby","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2025.107697_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13060","article-title":"The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors","volume":"32","author":"Bale","year":"2022","journal-title":"Brain Pathol."},{"key":"10.1016\/j.phrs.2025.107697_bib35","series-title":"Stem Cell Protocols","first-page":"263","article-title":"Isolation and Culture of Primary Glioblastoma Cells from Human Tumor Specimens","author":"Seidel","year":"2015"},{"key":"10.1016\/j.phrs.2025.107697_bib36","doi-asserted-by":"crossref","first-page":"17935","DOI":"10.1038\/s41598-017-18068-5","article-title":"BIGL: biochemically intuitive generalized loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism","volume":"7","author":"Van der Borght","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107697_bib37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","article-title":"A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2025.107697_bib38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ncb836","article-title":"Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism","volume":"4","author":"Bota","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107697_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kfh162","article-title":"Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity","volume":"80","author":"Vassallo","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.phrs.2025.107697_bib40","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","article-title":"Structure property relationships of carboxylic acid isosteres","volume":"59","author":"Lassalas","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107697_bib42","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/neuonc\/noq102","article-title":"Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions","volume":"12","author":"Vik-Mo","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib43","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1212\/WNL.0b013e318212a89f","article-title":"Neural stem\/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy","volume":"76","author":"Gong","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2025.107697_bib44","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1215\/15228517-2008-084","article-title":"Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy","volume":"11","author":"Rutkowski","year":"2009","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib46","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/jns.12338","article-title":"Bortezomib and other proteosome inhibitors\u2014induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.phrs.2025.107697_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.204","article-title":"Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species","volume":"4","author":"Cheng","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.107697_bib48","unstructured":"Roth, P., et al. EORTC 1709\/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. in ASCO Annual Meeting, Vol. Central Nervous System Tumors (2021)."},{"key":"10.1016\/j.phrs.2025.107697_bib49","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib50","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.107697_bib51","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1200\/jco.2011.29.15_suppl.2056","article-title":"Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma","volume":"29","author":"Bota","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107697_bib52","article-title":"Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: phase I\/II clinical trial data","author":"Bota","year":"2021","journal-title":"Neurooncol Adv. 3, vdab142-vdab142"},{"key":"10.1016\/j.phrs.2025.107697_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41416-019-0641-0","article-title":"Aconitase 2 inhibits the proliferation of MCF-7 cells promoting mitochondrial oxidative metabolism and ROS\/FoxO1-mediated autophagic response","volume":"122","author":"Ciccarone","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.107697_bib54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1515\/BC.2003.066","article-title":"Modulation of the chymotrypsin-like activity of the 20S proteasome by intracellular redox status: effects of glutathione peroxidase-1 overexpression and antioxidant drugs","volume":"384","author":"Kretz-Remy","year":"2003","journal-title":"Biol. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:37:03Z","timestamp":1778582223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":54,"alternative-id":["S1043661825001227"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107697","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}